On Demand Webinar

Tumor Organoids: A Paradigm Shift in Oncology Drug Discovery

More clinically relevant models are urgently needed for preclinical oncology drug development. This webcast demonstrates how tumor organoids can better predict patient response, improve the success rate of new anticancer agents, and overcome high oncology drug attrition rates.

The speakers describe HUB Organoid™ features that preserve the genetic and phenotypic characteristics of the original tumor, providing a unique in vitro system for screening the efficacy of oncological drugs and enabling improved cancer drug candidates to enter the clinic.

Watch This Webinar to Learn:

• The features of HUB Organoids
• Why HUB Organoids are considered to be superior 3D in vitro systems
• How to apply HUB Organoids to oncology drug development

Who Should Watch:

• Drug developers interested in understanding the benefit of tumor organoids compared to standard 3D systems
• Decision makers from biotech and pharmaceutical companies who are looking to enhance the translatability of their early stage drug development programs
• Researchers interested in learning about HUB tumor organoids and their predictive power

Watch Now!

About The Presenters:

Henry QX Li, PhD leads Crown Bioscience's Global Scientific Research and Innovation Division, focused on accelerating the creation of new, innovative products and services for discovery and translational sciences. Prior to this, Dr. Li successfully led and expanded Crown Bioscience’s patient-derived xenograft (PDX) based Translational Oncology platform (2011-2016), and led the Biomarker and Diagnostic Technologies Division developing novel proprietary translational technologies for precise cancer diagnosis, predictive biomarker discovery, immuno-oncology biomarker detection and quantification, as well as rare cell identification and characterization (2016-2018). Before joining Crown Bioscience, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.

Sylvia F Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells. With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a group leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of the HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the Organoids for the response of patients to certain treatments.